Evidence map›Paper›PMID 26949570›Full record

ReviewCurrent obstetrics and gynecology reports

Male Hormonal Contraception: Where Are We Now?

Christina Wang, Mario P R Festin, Ronald S Swerdloff

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current obstetrics and gynecology reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 61 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Emerging approaches to male contraception.Fertility and sterility · 2021
    Review
  10. Update on Novel Hormonal and Nonhormonal Male Contraceptive Development.The Journal of clinical endocrinology and metabolism · 2021
    Review
  11. Male Contraception.The Yale journal of biology and medicine · 2020
    Review
  12. Article
  13. Current and future trends in men's health clinics.Translational andrology and urology · 2020
    Review
  14. Article
  15. Article
  16. Review
  17. The future of male contraception: a fertile ground.Translational andrology and urology · 2018
    Review
  18. Article
  19. Pipeline for contraceptive development.Fertility and sterility · 2016
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Christina WangClinical and Translational Science Institute, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, 1000 W. Carson Street, Torrance, CA 90509 USA ; Division of Endocrinology, Department of Medicine, Harbor-UCLA Medical Center, 1000 W. Carson Street, Torrance, CA 90509 USA.
Mario P R FestinUNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development, and Research Training in Human Reproduction, World Health Organization, 20 Avenue Appia, CH 1211 Geneva, Switzerland.
Ronald S SwerdloffDivision of Endocrinology, Department of Medicine, Harbor-UCLA Medical Center, 1000 W. Carson Street, Torrance, CA 90509 USA.
Harbor–UCLA Medical Center · USThe Lundquist Institute · USWorld Health Organization · CH

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
NCATS NIH HHS UL1 TR000124NICHD NIH HHS HHSN275200800044UWorld Health Organization 001
6 · The paper itself

Abstract

Hormonal male contraception clinical trials began in the 1970s. The method is based on the use of exogenous testosterone alone or in combination with a progestin to suppress the endogenous production of testosterone and spermatogenesis. Studies using testosterone alone showed that the method was very effective with few adverse effects. Addition of a progestin increases the rate and extent of suppression of spermatogenesis. Common adverse effects include acne, injection site pain, mood change including depression, and changes in libido that are usually mild and rarely lead to discontinuation. Current development includes long-acting injectables and transdermal gels and novel androgens that may have both androgenic and progestational activities. Surveys showed that over 50 % of men will accept a new male method and female partners will trust their partner to take oral "male pills." Partnership between government, nongovernment agencies, academia, and industry may generate adequate interest and collaboration to develop and market the first male hormonal contraception.

Indexed as

AndrogensContraceptive efficacyMale contraceptionProgestinsSpermatogenesis suppression

Identifiers

PMID26949570
PMCPMC4762912
OpenAlexW2254534866

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.